Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMGHQJ8)

Drug Name
N-(phosphonacetyl)-L-aspartate Drug Info
Synonyms
Sparfosic acid; PALA; n-(phosphonacetyl)-l-aspartic acid; N-(Phosphonoacetyl)-L-aspartic acid; Sparfosic Acid [INN]; NSC-224131; UNII-78QVZ7RG8L; 51321-79-0; L-ASPARTIC ACID, N-(PHOSPHONOACETYL)-; N-Phosphonacetyl-L-aspartate; Phosphonacetyl-L-aspartic acid; Acidum sparfosicum [INN-Latin]; Acido sparfosico [INN-Spanish]; Acide sparfosique [INN-French]; N-(Phosphonoacetyl)-asparaginsaeure; N-(Phosphonacetyl)-L-Aspartate; 78QVZ7RG8L; (2S)-2-[(2-phosphonoacetyl)amino]butanedioic acid; Acido sparfosico; Acide sparfosique; Acidum; SPARFOSIC ACID
Cross-matching ID
PubChem CID
46926274
TTD Drug ID
D0L6CN

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.27 0.00e+0 34/36 (94.44%) MCM3;FEN1;MCM5;...
Proteasome 2.19 0.00e+0 44/46 (95.65%) PSMC1;PSMD2;PSMC3;...
Mismatch repair 2.18 0.00e+0 22/23 (95.65%) MSH2;MLH1;PCNA;...
Pyrimidine metabolism 2.11 0.00e+0 40/56 (71.43%) RRM2;TYMS;TK1;...
Spliceosome 2.09 0.00e+0 101/150 (67.33%) HSPA8;SRSF7;DDX23;...
Ribosome biogenesis in eukaryotes 1.94 1.14e-3 52/108 (48.15%) NOP56;RAN;POP4;...
Fanconi anemia pathway 1.87 4.91e-3 36/54 (66.67%) FANCL;MLH1;RAD51C;...
Cell cycle 1.83 5.15e-3 110/124 (88.71%) CCNB2;MCM3;CCNE2;...
RNA transport 1.82 6.10e-3 128/186 (68.82%) EIF1AY;NUP85;RAN;...
Aminoacyl-tRNA biosynthesis 1.76 1.30e-2 15/66 (22.73%) LARS2;SARS2;DARS2;...
Oocyte meiosis 1.72 2.12e-2 90/129 (69.77%) PRKACB;CCNB2;CCNE2;...
Nucleotide excision repair 1.65 4.29e-2 40/47 (85.11%) PCNA;RPA2;RFC3;...
Pyruvate metabolism -1.63 4.54e-2 41/47 (87.23%) ADH1A;ACACA;ALDH3A2;...
Glycerolipid metabolism -1.64 4.07e-2 44/61 (72.13%) AGPAT1;DGKI;DGAT1;...
Parathyroid hormone synthesis, secretion and action -1.66 3.65e-2 98/106 (92.45%) MEF2A;GNAI1;CREB5;...
MicroRNAs in cancer -1.68 2.90e-2 146/310 (47.1%) PTEN;RPS6KA5;MYC;...
Protein export -1.69 2.87e-2 17/23 (73.91%) SEC11A;SRPRA;SEC63;...
Basal cell carcinoma -1.69 2.99e-2 41/63 (65.08%) FZD1;APC2;CTNNB1;...
Melanogenesis -1.70 3.06e-2 74/101 (73.27%) GNAO1;MAP2K1;TYR;...
Protein processing in endoplasmic reticulum -1.70 3.20e-2 127/171 (74.27%) SAR1A;FBXO2;DNAJC1;...
Metabolism of xenobiotics by cytochrome P450 -1.70 3.17e-2 49/77 (63.64%) CYP2D6;CYP1A2;ADH1C;...
Synthesis and degradation of ketone bodies -1.71 3.26e-2 9/10 (90%) HMGCL;BDH2;BDH1;...
Regulation of lipolysis in adipocytes -1.71 3.43e-2 52/55 (94.55%) PIK3R2;PIK3CB;GNAI2;...
Complement and coagulation cascades -1.72 3.06e-2 76/85 (89.41%) C9;SERPINC1;SERPINA5;...
Glycine, serine and threonine metabolism -1.73 3.24e-2 31/40 (77.5%) SHMT2;DLD;PSPH;...
Endometrial cancer -1.73 3.44e-2 56/58 (96.55%) PDPK1;MAP2K1;TCF7;...
Acute myeloid leukemia -1.74 2.99e-2 66/67 (98.51%) PIK3R2;BRAF;STAT5B;...
Longevity regulating pathway -1.74 3.20e-2 90/151 (59.6%) RHEB;PIK3R2;ATF2;...
Thyroid cancer -1.75 3.45e-2 36/37 (97.3%) MAP2K1;PPARG;TCF7;...
Phospholipase D signaling pathway -1.76 3.09e-2 134/148 (90.54%) RRAS;RHEB;PIK3R2;...
mTOR signaling pathway -1.77 3.26e-2 114/154 (74.03%) RHEB;PIK3R2;BRAF;...
Proximal tubule bicarbonate reclamation -1.81 2.56e-2 21/23 (91.3%) GLUD2;SLC4A4;ATP1B2;...
Ferroptosis -1.81 2.56e-2 36/41 (87.8%) TF;GCLM;GCLC;...
Insulin resistance -1.83 2.40e-2 96/108 (88.89%) PRKAB1;PIK3CB;OGT;...
Adipocytokine signaling pathway -1.84 2.74e-2 64/69 (92.75%) LEP;PRKAB1;ACSBG1;...
AMPK signaling pathway -1.86 2.13e-2 106/120 (88.33%) PPP2R2B;RHEB;PIK3R2;...
FoxO signaling pathway -1.88 1.02e-2 118/131 (90.08%) PIK3R2;BRAF;PRKAB1;...
PPAR signaling pathway -1.90 9.60e-3 66/74 (89.19%) ACSBG1;ACSL4;FABP5;...
Retinol metabolism -1.91 1.28e-2 41/68 (60.29%) RDH16;ADH1A;CYP3A7;...
Biosynthesis of unsaturated fatty acids -1.95 1.28e-2 21/27 (77.78%) BAAT;ELOVL4;SCP2;...
Steroid hormone biosynthesis -2.01 1.28e-2 43/61 (70.49%) CYP3A7;CYP19A1;AKR1C4;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 80uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 80uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 80uM 6H
HT-29 CVCL_0320 Homo sapiens 80uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 80uM 6H
MDST8 CVCL_1400 Homo sapiens 80uM 6H
NCI-H508 CVCL_1561 Homo sapiens 80uM 6H
SNU-1040 CVCL_5001 Homo sapiens 80uM 6H
SNU-C4 CVCL_5008 Homo sapiens 80uM 6H
SNU-C5 CVCL_5009 Homo sapiens 80uM 6H
SW480 CVCL_0546 Homo sapiens 80uM 6H
SW620 CVCL_0547 Homo sapiens 80uM 6H
SW948 CVCL_0550 Homo sapiens 80uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 80uM 6H
HT115 CVCL_1294 Homo sapiens 80uM 6H
RKO CVCL_0504 Homo sapiens 80uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 80uM 6H
SNG-M CVCL_1707 Homo sapiens 80uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 80uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 80uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 80uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 80uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 80uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 80uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 80uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 80uM 6H
T3M-10 CVCL_1729 Homo sapiens 80uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 80uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 80uM 6H
HCC515 CVCL_5134 Homo sapiens 80uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 80uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 80uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 80uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 80uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 80uM 6H
OV7 CVCL_1623 Homo sapiens 80uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 80uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 80uM 6H
RMUG-S CVCL_1666 Homo sapiens 80uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 80uM 6H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 80uM 6H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 80uM 6H
PL-21 CVCL_2161 Homo sapiens 80uM 6H
SKM-1 CVCL_0010 Homo sapiens 80uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 80uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 80uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 80uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 80uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 80uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 80uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 80uM 6H